{
  "id": "5890dcba621ea6ff7e000003",
  "type": "summary",
  "question": "What is the mechanism of action of onartuzumab?",
  "ideal_answer": "Onartuzumab is monoclonal antibody targeting MET. It works by inhibiting MET. Onartuzumab was tested for treatment of non-small cell lung carcinoma, adenocarcinoma of the stomach and gastroesophageal Junction, and recurrent glioblastoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23922054",
    "http://www.ncbi.nlm.nih.gov/pubmed/22917884",
    "http://www.ncbi.nlm.nih.gov/pubmed/25806189",
    "http://www.ncbi.nlm.nih.gov/pubmed/27937096",
    "http://www.ncbi.nlm.nih.gov/pubmed/25074413",
    "http://www.ncbi.nlm.nih.gov/pubmed/27349303",
    "http://www.ncbi.nlm.nih.gov/pubmed/24101053",
    "http://www.ncbi.nlm.nih.gov/pubmed/27918764",
    "http://www.ncbi.nlm.nih.gov/pubmed/24687921",
    "http://www.ncbi.nlm.nih.gov/pubmed/26445503",
    "http://www.ncbi.nlm.nih.gov/pubmed/23894056",
    "http://www.ncbi.nlm.nih.gov/pubmed/25522765",
    "http://www.ncbi.nlm.nih.gov/pubmed/24493831",
    "http://www.ncbi.nlm.nih.gov/pubmed/25777467",
    "http://www.ncbi.nlm.nih.gov/pubmed/24258345",
    "http://www.ncbi.nlm.nih.gov/pubmed/24959087",
    "http://www.ncbi.nlm.nih.gov/pubmed/27856142",
    "http://www.ncbi.nlm.nih.gov/pubmed/23882082",
    "http://www.ncbi.nlm.nih.gov/pubmed/27401892",
    "http://www.ncbi.nlm.nih.gov/pubmed/27918718",
    "http://www.ncbi.nlm.nih.gov/pubmed/23063071",
    "http://www.ncbi.nlm.nih.gov/pubmed/23536720",
    "http://www.ncbi.nlm.nih.gov/pubmed/25818471",
    "http://www.ncbi.nlm.nih.gov/pubmed/23810377"
  ],
  "snippets": [
    {
      "text": " In this study, e-training was used to train board-certified pathologists to evaluate non-small cell lung carcinoma for eligibility for treatment with onartuzumab, a MET-inhibiting agent.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27349303",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "MET immunohistochemistry expression as a biomarker of onartuzumab activity was also examined.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: The addition of onartuzumab to mFOLFOX6 in gastric cancer did not improve efficacy in an unselected population or in a MET immunohistochemistry-positive population.IMPLICATIONS FOR PRACTICE: The YO28252 study demonstrated that the addition of the anti-MET agent onartuzumab to mFOLFOX6 for treatment of gastric cancer did not improve efficacy in an overall study population or those selected for positive MET status by immunohistochemistry.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The phase II study GO27819 investigated the monovalent MET inhibitor onartuzumab plus bevacizumab (Ona + Bev) versus placebo plus bevacizumab (Pla + Bev) in recurrent glioblastoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27918718",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We report results of METGastric, a phase 3 trial of the MET inhibitor onartuzumab plus standard first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative, MET-positive, advanced GEC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27918764",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion Onartuzumab plus erlotinib did not improve clinical outcomes, with shorter OS in the onartuzumab arm, compared with erlotinib in patients with MET-positive non-small-cell lung cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27937096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A recent example of a failed trial is the Phase III MetLung trial that compared the effects of the c-MET monovalent antibody onartuzumab with erlotinib versus erlotinib alone in late-stage non-small-cell lung cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25818471",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23882082",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Because onartuzumab, a monovalent antibody to MET, blocks HGF-induced MET activation, the addition of onartuzumab to erlotinib may improve therapeutic efficacy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25522765",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Because binding of sMET to onartuzumab in circulation resulted in increasing sMET serum concentrations due to reduced clearance, this likely renders sMET unsuitable as a pharmacodynamic biomarker for onartuzumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24258345",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Onartuzumab, a humanized, monovalent monoclonal anti-MET antibody, antagonizes MET signaling by inhibiting binding of its ligand, hepatocyte growth factor (HGF).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24258345",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23882082",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24258345",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Onartuzumab, a recombinant humanized monovalent monoclonal antibody directed against MET, the receptor for the hepatocyte growth factor, has been investigated for the treatment of solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26445503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Successful therapeutic targeting of the MET/HGF pathway has been achieved using monoclonal antibodies against the MET receptor and its ligand HGF in addition to MET-specific and multitargeted small-molecule tyrosine-kinase inhibitors with several drugs in late-phase clinical trials including onartuzumab, rilotumumab, tivantinib, and cabozantinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24959087",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Grade 3-5 adverse events (AEs) were seen in 88.3% of patients receiving onartuzumab and in 78.3% of patients receiving placebo, with serious AEs in 55% and 40%, respectively.The addition of onartuzumab to mFOLFOX6 in gastric cancer did not improve efficacy in an unselected population or in a MET immunohistochemistry-positive population.The YO28252 study demonstrated that the addition of the anti-MET agent onartuzumab to mFOLFOX6 for treatment of gastric cancer did not improve efficacy in an overall study population or those selected for positive MET status by immunohistochemistry.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23882082",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228"
  ]
}